EGFR and neoplasm: Niederst et al. reported that RB loss was detected in 100% of the 10 SCLC-transformed EGFR mutants late in tumor progression, which is associated with increased neuroendocrine marker and decreased EGFR expression when compared with resistant NSCLC [59].